Skip to main content

Table 2 Baseline characteristics of patients who developed T2DM

From: Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

Baseline characteristics

Subjects with incident T2DM

Subjects without incident T2DM

n (%)

n (%)

All patients (n = 2,016,094)

130,395 (6.47)

1,885,699 (93.53)

Gender

  

Male

70,972 (54.43)

995,813 (52.81)

Female

59,423 (45.57)

889,886 (47.19)

Age mean (sd), yrs

63.44 (10.54)

62.19 (11.24)

30-39

1,697 (1.30)

43,108 (2.29)

40-49

11,324 (8.68)

209,938 (11.13)

50-59

33,703 (25.85)

522,025 (27.68)

60-69

43,636 (33.46)

592,927 (31.44)

70-79

32,174 (24.67)

389,694 (20.67)

80-85

7,861 (6.03)

128,007 (6.79)

BMI, kg/m 2

  

 <20

2,461 (1.89)

74,258 (3.94)

 20-25

20,947 (16.06)

544,004 (28.85)

 >25

102,001 (78.22)

1,020,270 (54.11)

 Unknown

4,986 (3.82)

247,167 (13.11)

Smoking status

  

Current smokers

21,742 (16.67)

335,261 (17.78)

Former smoker

59,403 (45.56)

636,260 (33.74)

Non-smoker/never

48,775 (37.41)

833,493 (44.20)

Unknown status

475 (0.36)

80,685 (4.28)

Alcohol use

  

Current (unknown amount)

5,044 (3.87)

59,727 (3.17)

Rare drinker (<2u/d)

21,939 (16.83)

271,032 (14.37)

Moderate drinker (3-6u/d)

64,639 (49.57)

916,543 (48.60)

Excessive drinker (>6u/d)

40,912 (9.49)

135,790 (8.57)

Past use

4,200 (3.22)

44,267 (2.35)

Non-drinker

17,844 (13.68)

197,361 (10.47)

Unknown status

5,809 (4.45)

230,987 (12.25)

Family history of:

  

Diabetes

6,607 (5.07)

67,269 (3.57)

Cardiovascular disease

29,012 (22.25)

391,498 (20.76)

Diagnosis of:

  

Hyperlipidaemia

6,372 (4.89)

53,045 (2.81)

Atherosclerosis

373 (0.29)

3.466 (0.18)

Hypertension

50,529 (38.75)

478,788 (25.39)

Heart failure

3,235 (2.48)

27,373 (1.45)

Cardiovascular disease

20,852 (15.99)

179,553 (9.52)

Atrial fibrillation

5,117 (3.92)

48,795 (2.59)

Hepatic disease (within 6 months)

787 (0.60)

6,757 (0.36)

Kidney disease (within 6 months)

2,671 (2.05)

38,494 (2.04)

Abnormal glucose level

3,780 (2.90)

14,053 (0.75)

Osteoporosis

3,099 (2.38)

55,210 (2.93)

Cancer

12,916 (9.91)

189,677 (10.06)

Thyroid disease

10,747 (8.24)

129,671 (6.88)

Prior use of:

  

Antipsychotics (within 6 months)

114 ( 0.09)

1,455 (0.08)

Antidepressants (within 6 months)

1,503 (1.15)

19,868 (1.05)

Cardiovascular drugs

53,096 (40.72)

680,014 (36.06)

Nonstatin lipid lowerers (within 3 months)

189 (0.14)

1,041 (0.06)

Systemic glucocorticoids (within 6 months)

1,496 (1.15)

18,475 (0.98)

Oestrogens/HRT (within 1 year)

706 (0.54)

8,781 (0.47)

Bisphosphonates

699 (0.54)

11,765 (0.62)

CYP450 3A4 inhibitor

1,709 (1.31)

18,616 (0.99)

Annual consultation rate, mean (SD)

22.16 (19.33)

17.66 (18.04)

Annual prescription rate, mean (SD)

19.42 (30.12)

11.57 (24.27)

  1. All the differences between groups were significant at the 0.05 level (two-sided).